ORLANDO, Florida (Reuters) - A study of blockbuster drug Avastin in colon cancer patients who have undergone surgery showed that the drug's effectiveness wore off after patients stopped taking it, ...

– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...

In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1 Up to 80% of people with this ...

The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and ...

November 18, 2011 — The US Food and Drug Administration (FDA) announced today that it is rescinding its approval of bevacizumab (Avastin, Genentech) for treating metastatic breast cancer because the ...

The final overall survival results of the PAOLA-1/ENGOT-ov25 trial confirmed the drug combination as “one of the standards of care” for some populations of patients with ovarian cancer. Maintenance ...

The UK's National  Institute for Health and Clinical Excellence (NICE) announced in a draft guidance it will not approve Roche's breast cancer drug Avastin (bevacizumab) due to "too many ...

Firm says ovarian cancer is the fifth tumor type Avastin is now approved for in Europe. The EC approved Roche’s Avastin in combination with standard carboplatin and paclitaxel chemotherapy as ...

December 9, 2011 (San Antonio, Texas) — Mere weeks after the US Food and Drug Administration (FDA) rescinded approval of the use of bevacizumab (Avastin, Genentech) in metastatic breast cancer, a new ...

– In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28% – – Up to 80% of people with ...